Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies

FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies

4 Best High-Yield Stocks on the S&P 500: Phillips 66, Gilead, Valero, and Walgreen Boots

4 Best High-Yield Stocks on the S&P 500: Phillips 66, Gilead, Valero, and Walgreen Boots

The stock market has been experiencing high volatility due to surging inflation, the Ukraine-Russia war, and multiple interest rate increases planned by the Fed this year. So, investors looking to side-step the market’s volatility could be well served by betting on high dividend-yielding stocks. Gilead Sciences (GILD), Walgreens Boots Alliance…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection

The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ:GILD) application for lenacapavir for heavily treated multi-drug resistant (MDR) HIV-1 infection. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the…

Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients

Gilead Sciences Inc (NASDAQ: GILD)

Hookipa Pharma Stock Surges On HIV Pact With Gilead

Hookipa Pharma Inc (NASDAQ: HOOK)

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa

Here's a roundup of top developments in the biotech space over the last 24 hours.

Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

Gilead Sciences Inc (NASDAQ: GILD)

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).

GSK claims $1.2bn victory in HIV patent battle with US rival Gilead

GSK claims $1.2bn victory in HIV patent battle with US rival Gilead

Drugmaker GlaxoSmithKline today claimed a landmark victory in its competitive battle to dominate HIV treatment as a US rival agreed to hand over $1.25 billion to end a high-stakes global patent dispute.

Evening Standard

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Sciences Inc (NASDAQ: GILD) posted

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100's of premium titles.
One news app.

FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years.

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to

1 … 5 6 7 8

Organisations

US Federal Reserve

Gilead Sciences Inc

Walgreens Boots Alliance

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

383,820 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play